La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Torrent Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Samir Mehta

Amministratore delegato

₹260.0m

Compenso totale

Percentuale dello stipendio del CEO	0.02%
Mandato del CEO	35.6yrs
Proprietà del CEO	0.0002%
Durata media del management	2yrs
Durata media del Consiglio di amministrazione	2.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Samir Mehta rispetto agli utili di Torrent Pharmaceuticals?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	₹17b
Mar 31 2024	₹260m	₹40k	₹17b
Dec 31 2023	n/a	n/a	₹15b
Sep 30 2023	n/a	n/a	₹13b
Jun 30 2023	n/a	n/a	₹13b
Mar 31 2023	₹230m	₹40k	₹12b
Dec 31 2022	n/a	n/a	₹8b
Sep 30 2022	n/a	n/a	₹8b
Jun 30 2022	n/a	n/a	₹8b
Mar 31 2022	₹200m	₹40k	₹8b
Dec 31 2021	n/a	n/a	₹12b
Sep 30 2021	n/a	n/a	₹13b
Jun 30 2021	n/a	n/a	₹13b
Mar 31 2021	₹200m	₹40k	₹13b
Dec 31 2020	n/a	n/a	₹12b
Sep 30 2020	n/a	n/a	₹12b
Jun 30 2020	n/a	n/a	₹11b
Mar 31 2020	₹200m	₹40k	₹10b
Dec 31 2019	n/a	n/a	₹6b
Sep 30 2019	n/a	n/a	₹6b
Jun 30 2019	n/a	n/a	₹5b
Mar 31 2019	₹150m	₹40k	₹4b
Dec 31 2018	n/a	n/a	₹8b
Sep 30 2018	n/a	n/a	₹6b
Jun 30 2018	n/a	n/a	₹7b
Mar 31 2018	₹150m	₹40k	₹7b

Compensazione vs Mercato: La retribuzione totale di Samir ($USD 3.10M ) è superiore alla media delle aziende di dimensioni simili nel mercato Indian ($USD 1.22M ).

Compensazione vs guadagni: La retribuzione di Samir è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Samir Mehta (60 yo)

35.6yrs

Mandato

₹260,040,000

Compensazione

Mr. Samir Uttamlal Mehta, B.Com., MBA serves as a Managing Director of Torrent Pharmaceuticals Limited since 1989. Mr. Mehta served as Managing Director of Torrent Power Limited. Mr. Mehta has been associa...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Samir Mehta	Executive Chairman & MD	no data	₹260.04m	0.00024% ₹ 2.7m
Aman Mehta	Whole-Time Director	2yrs	₹65.88m	0.000060% ₹ 680.4k
Sudhir Menon	Chief Financial Officer	5.9yrs	₹16.30m	Nessun dato
Chintan Trivedi	Company Secretary & Compliance Officer	2yrs	Nessun dato	Nessun dato
Ashish Hajarnish	Executive Director	less than a year	₹8.25m	Nessun dato
Abdullah Said Al Abri	Chief Customer Service Officer	3.2yrs	Nessun dato	Nessun dato
Jaydip Bhatt	Vice President of Human Resource	no data	₹6.56m	Nessun dato

2.0yrs

Durata media

58yo

Età media

Gestione esperta: Il team dirigenziale di 500420 è considerato esperto (durata media dell'incarico 2 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Samir Mehta	Executive Chairman & MD	35.6yrs	₹260.04m	0.00024% ₹ 2.7m
Aman Mehta	Whole-Time Director	2yrs	₹65.88m	0.000060% ₹ 680.4k
Ashish Hajarnish	Executive Director	less than a year	₹8.25m	Nessun dato
Sudhir Mehta	Chairman Emeritus	10.1yrs	Nessun dato	0.00030% ₹ 3.4m
Nikhil Khattau	Independent Director	less than a year	₹2.60m	Nessun dato
Manish Choksi	Independent Director	2.1yrs	₹4.30m	Nessun dato
Ameera Shah	Independent Director	6yrs	₹4.90m	0.00052% ₹ 5.9m
Nayantara Bali	Independent Director	5.4yrs	₹6.70m	Nessun dato
Jinal Mehta	Non-Executive Director	less than a year	Nessun dato	Nessun dato
Maurice Chagnaud	Independent Director	2.3yrs	₹6.30m	Nessun dato

2.2yrs

Durata media

58yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 500420 non è considerato esperto (durata media del mandato 2.2 anni), il che suggerisce un nuovo consiglio.

Torrent Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Torrent Pharmaceuticals Limited Announces Promotion of Ashish Hajarnis as Executive Director from Vice President

High number of new directors

Torrent Pharmaceuticals Limited, Annual General Meeting, Jul 23, 2024

Torrent Pharmaceuticals Limited Announces Stepping Down of Jinesh Shah as the Director, Effective from 23 July 2024

Torrent Pharmaceuticals Limited Announces Change in Directorate , Effective 31 March 2024

Torrent Pharmaceuticals Limited Announces Superannuation of Ashok Modi as Executive Director

Recent updates

Torrent Pharma Reportedly is Said to Seek Raising $3 Billion for KKR's Stake in JB Chemicals

Torrent Pharmaceuticals Reportedly in Talks to Acquire KKR’s Stake in JB Chemicals

Price target increased by 8.1% to ₹3,133

Torrent Pharmaceuticals Limited Announces Promotion of Ashish Hajarnis as Executive Director from Vice President

Torrent Pharmaceuticals Limited to Report Q1, 2025 Results on Jul 23, 2024

High number of new directors

Torrent Pharmaceuticals Limited, Annual General Meeting, Jul 23, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

Torrent Pharmaceuticals Limited Announces Stepping Down of Jinesh Shah as the Director, Effective from 23 July 2024

Torrent Pharmaceuticals Limited to Report Fiscal Year 2024 Results on May 24, 2024

Torrent Pharmaceuticals Limited Announces Change in Directorate , Effective 31 March 2024

Torrent Pharmaceuticals Limited Announces Superannuation of Ashok Modi as Executive Director

Upcoming dividend of ₹22.00 per share at 0.8% yield

Price target increased by 7.1% to ₹2,427

Dividend increased to ₹22.00

Third quarter 2024 earnings: EPS exceeds analyst expectations

Torrent Pharmaceuticals Limited Announces Interim Dividend, Payable on or around 23 February, 2024

Torrent Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 02, 2024

Torrent Pharmaceuticals Reportedly Bid to Acquire the Stake of Cipla Stalled over Valuation Differences

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Torrent Pharma Calls the Reports of Cipla Acquisition as Speculative

Family Rift Clouds $7 Billion Sale of Cipla

Torrent Pharmaceuticals Limited to Report Q2, 2024 Results on Oct 23, 2023

Torrent Pharma Reportedly in Advance Talks with CVC Capital to Buyout Cipla Promoters

Torrent Pharmaceutical Leads in the Race to Acquire Cipla

Torrent Reportedly in Top Gear to Close Out Cipla Buyout, in Talks with PES, Banks for Funds

Food and Drug Administration Issues an Establishment Inspection Report for the Torrent Pharmaceuticals Limited's Manufacturing Facility At Dahej, Gujarat

Torrent Reportedly Joins Fray for Hamied Family Stake in Cipla

Price target increased by 8.1% to ₹2,037

Torrent Pharmaceuticals Limited Declares Final Dividend for the Financial Year Ended 31 March, 2023

Full year 2023 earnings: EPS misses analyst expectations

Torrent Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 07, 2023

Torrent Pharmaceuticals Limited, Annual General Meeting, Aug 07, 2023

Torrent Pharmaceuticals Limited Recommends Final Dividend, Payable on or Around 14 August, 2023

Full year 2023 earnings: EPS misses analyst expectations

Torrent Pharmaceuticals Limited to Report Q4, 2023 Results on May 30, 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Torrent Pharmaceuticals Limited Approves an Interim Dividend, Payable on or Around 14 February 2023

Torrent Pharmaceuticals Limited to Report Q3, 2023 Results on Jan 25, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Torrent Pharmaceuticals Limited (BSE:500420) completed the acquisition of Curatio Healthcare (I) Pvt Ltd.

Torrent Pharmaceuticals Limited to Report Q2, 2023 Results on Oct 21, 2022

Torrent Pharmaceuticals Limited (BSE:500420) entered into an agreement to acquire Curatio Healthcare (I) Pvt Ltd for INR 20 billion.

Torrent Pharma Reportedly Set to Acquire Curatio

Less than half of directors are independent

Torrent Pharmaceuticals Announces Appointment of Aman Mehta as Director on the Board of Torrent Pharma from 1st August, 2022

Price target increased to ₹1,719

Torrent Pharmaceuticals Limited to Report Q1, 2023 Results on Jul 29, 2022

Full year 2022 earnings: EPS misses analyst expectations

Torrent Pharmaceuticals Limited, Annual General Meeting, Jul 29, 2022

Full year 2022 earnings: EPS misses analyst expectations

Torrent Pharmaceuticals Limited (BSE:500420) entered into an agreement to acquire Styptovit-E, Finast, Finast-T and Dynapress brands from Dr. Reddy's Laboratories Limited (BSE:500124).

Torrent Pharmaceuticals Limited Recommends Special Dividend, Payable on or Around 4 August, 2022

Insufficient new directors

Torrent, JB Chemicals Reportedly in Final Race to Acquire Curatio Healthcare

Insufficient new directors

Dr Reddy's, Biocon Reportedly Among 6 Drug Companies in Race for Curatio

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Second quarter 2022 earnings released: EPS ₹18.63 (vs ₹18.32 in 2Q 2021)

Full year 2021 earnings released: EPS ₹73.98 (vs ₹60.56 in FY 2020)

Independent Non Executive Director recently bought ₹20m worth of stock

Upcoming dividend of ₹15.00 per share

Independent Non Executive Director recently bought ₹5.0m worth of stock

Torrent Pharmaceuticals Limited Recommends Final Dividend, Payable on or Around July 30, 2021

Full year 2021 earnings released: EPS ₹73.98 (vs ₹60.56 in FY 2020)

Sun Pharmaceutical, Dr Reddy's Labs, JB Pharmaceuticals, Torrent Pharma and Piramal Pharma Reportedly Eye Oaknet Healthcare

New 90-day low: ₹2,520

Earnings beat expectations, revenue disappoints